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Abstract Cancer is a major public health concern in both
developed and developing countries. Several plant-derived
anti-cancer agents including taxol, vinblastine, vincristine,
the campothecin derivatives, topotecan, irinotecan and
etoposide are in clinical use all over the world. Other
promising anti-cancer agents include flavopiridol, rosco-
vitine, combretastatin A-4, betulinic acid and silvestrol.
From this list one can well imagine the predominance of
polyphenols, flavonoids and their synthetic analogs in the
treatment of ovarian, breast, cervical, pancreatic and
prostate cancer. Flavonoids present in human diet comprise
many polyphenolic secondary metabolites with broad-
spectrum pharmacological activities including their
potential role as anti-cancer agents. A positive correlation
between flavonoids-rich diet (from vegetables and fruits)
and lower risk of colon, prostate and breast cancers lead to
a question that whether flavonoids mediate the protective
effects as chemopreventive agents or can interact with
different genes and proteins to play role in chemotherapy.
The current review emphasizes onto the therapeutic
potential of flavonoids and their synthetic analogs as anti-
cancer agents by providing new insights into the factors,
regulation and molecular mechanisms along with their
significant protein interactions.
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Introduction
Cancer chemoprevention, by the use of natural, dietary or
synthetic agents that can reverse, suppress or prevent carcin-
ogenic progression, has become an appealing strategy to
combat the dogma associated with increasing cases of cancers
worldwide (Tsao and Edward 2004). Epidemiological studies
point to the fact that long-term consumption of diet rich in
foods and vegetables reduces the risk of chronic diseases
especially cancer (Wallstrom et al. 2000; Parr and Bolwell
2000; Arts and Hollman 2005; Patel 2008; Xiao et al. 2011).
Such diets can minimize—exposure to deleterious sub-
stances, activation of procarcinogens and can maximize the
intake of certain beneficial nutrients like isothiocyanates,
unsaturated fatty acids, polyphenolic terpenoids (PPT), sele-
nium, terpenes, etc. (Franco et al. 2004; Johnson 2004).
Historical perspective
In 1930, a new substance was isolated from oranges that can
reduce the capillary permeability and is believed to be a
member of a new class of vitamins hence designated as vita-
min P, however, later on this substance was identified as a
flavonoid (rutin). Flavonoids drew greater attention with the
decreased incidence of cardiovascular diseases, in spite of a
greater saturated fat intake in Mediterranean population,
which was associated with red wine consumption (Renaud and
de Lorgeril 1992). Flavonoids belong to a very vast group of
plant secondary metabolites with variable phenolic structures
and are found in fruits, vegetables, grains, bark, roots, stems,
flowers, tea and wine (Nijeveldt et al. 2001). In plants,
flavonoids are performing a variety of functions including
pollination, seed dispersal, pollen tube growth, resorption of
mineral nutrients, tolerance to abiotic stresses, protection
against ultraviolet and allelopathic interactions, etc. (Gould
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and Lister 2005; Samanta et al. 2011; Hassan and Mathesius
2012). More than 8,000 different compounds of polyphenols
have been known and that can be further subdivided into ten
different general classes (Ververidis et al. 2007; Harborne and
Williams 2000; Chahar et al. 2011). Flavonoids are part of this
family and have more than 4,000 varieties (Harborne 1994).
Isoflavonoids (phytoestrogens or non-steroidal estrogens)
such as the soy isoflavones—genistein and daidzein, have also
been known for their therapeutic significance particularly in
the protection of human health (Wiseman et al. 2000; Stevens
and Page 2004; Ørgaard and Jensen 2008; Xiao 2008; Og-
buewu et al. 2010; Wiseman et al. 2002). There are a variety of
factors such as species, variety, climate, degree of ripeness and
post harvest storage which influence the concentration of
flavonoids in foods (Holland et al. 1995; Robards and Antol-
ovich 1997; Pascual-Teresa et al. 2000; Modak et al. 2011).
Flavonoids have a remarkable reducing ability and ability to
interact with proteins (Haslam 1996; Havsteen 2002; Liu et al.
2010; McRae and Kennedy 2011). This review focus on bio-
chemical studies carried out to analyze the possible health
effects of flavonoids and to assess their potential in the pre-
vention of degenerative diseases or their therapeutic value as
potential drugs.
Structural insight and classification
Polyphenolic terpenoids are the most extensively studied
flavonoids which have a characteristic C6–C3–C6 struc-
ture. The chemical structure of flavonoids is based on a C15
skeleton with a CHROMANE ring bearing a second aro-
matic ring B in position 2, 3 or 4.
In a few cases, the six-membered heterocyclic ring C
occurs in an isomeric open form or is replaced by a five-
membered ring.
AURONES (2-benzyl-coumarone) 
They have been further subdivided into flavones,
flavonols, flavanones, flavanols, anthocyanins and isoflav-
ones based on the nature of C3 element (Fig. 1). Different
groups of flavonoids and their dietary sources are men-
tioned in Table 1. Flavonoids, especially flavanols, flavo-
nols and anthocyanins are relatively abundant in human
diet and possibly involved in prevention of cancers, car-
diovascular diseases and neurodegeneration (Bazzano et al.
2002; Clifford 2004; Atmani et al. 2009; Fang et al. 2010;
Xiao et al. 2011).
Synthesis
The flavonoids are formed in plants and participate in the
light-dependent phase of photosynthesis during which they
catalyze electron transport (Das 1994). They are synthe-
sized from the aromatic amino acids—phenylalanine and
tyrosine, together with acetate units (Heller and Forkmann
1993). Phenylalanine and tyrosine are converted to cin-
namic acid and parahydroxycinnamic acid, respectively, by
the action of phenylalanine and tyrosine ammonia lyases
(Wagner and Farkas 1975). Cinnamic acid (or parahydr-
oxycinnamic acid) condenses with acetate units to form the
cinnamoyl structure of the flavonoids (Fries rearrange-
ment). A variety of phenolic acids, such as caffeic acid,
ferulic acid, and chlorogenic acid, are cinnamic acid
derivatives. There is then alkali-catalyzed condensation of
an ortho-hydroxyacetophenone with a benzaldehyde
derivative generating chalcones and flavonones (Fig. 2),
as well as a similar condensation of an ortho-hydroxy-
acetophenone with a benzoic acid derivative (acid chlo-
ride or anhydride), leading to 2-hydroxyflavanones and
flavones (Heller and Forkmann 1993). The synthesis of
chalcones and anthocyanidins has been described in detail
by Dhar (1994). Biotransformation of flavonoids in the
gut can release these cinnamic acid (phenolic acids)
derivatives (Scheline 1991). In terms of their biosynthe-
sis, the phenyl propanoid pathway produces a range of
secondary metabolites such as phenolic acids, lignins,
lignans and stilbenes using phenyl alanine and tyrosine as
the precursor. After tannins, flavonoid glycosides are by
far the most common dietary sources of flavonoids.
Usually 110–121 mg/day of flavonoids has been recom-
mended as a healthy diet for an adult (Hertog et al. 1992,
1993a, 1993b).
Metabolism
The fate of orally and parenterally administered flavonoids
in mammals was reviewed by Griffiths and Barrow (1972)
and later by Hollman and Katan (1998). Considerable
information is available regarding the metabolism of
flavonoids in animals and to a very limited extent in
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humans (Hackett 1986; Scheline 1991). Hertog et al.
(1992) measured the content of potentially anti-carcino-
genic flavonoids of 28 vegetables, wine, and fruits fre-
quently consumed in The Netherlands and the measured
flavonoids were quercetin, kaempferol, myricetin, apige-
nin, and luteolin. The mean daily intake of these five anti-
oxidant flavonoids was 23 mg/day, which exceeds the
intake of other familiar anti-oxidants such as b-carotene
(2–3 mg/day) and vitamin E (7–10 mg/day) and is about
one-third the average intake of vitamin C (70–100 mg/day)
(Hertog et al. 1993b). Quercetin is the most important
contributor to the estimated intake of flavonoids, mainly
from the consumption of apples and onions (Knekt et al.
1996; Gibellini et al. 2011; Giuliani et al. 2008). It is
extremely difficult to estimate the daily human intake of
flavonoids, especially because of the lack of standardized
analytical methods (Scalbert and Williamson 2000).
However, the average daily intake of the most abundant
flavonoids, catechins, is *100 mg (Perez-Vizcaino et al.
2009). Similar to daily intake, it is also quite complex to
assess and quantify the bioavailability of flavonoids (Russo
2007). In countries such as Japan, Korea, China, and Tai-
wan, the mean daily intake of soy products has been esti-
mated to be in the range of 10–50 g compared to only
1–3 g in the United States (Messina et al. 1994).
Flavonoid pharmacokinetics is complex, since they are
usually contained as glucosides in fruits and vegetables,
cleaved and glucuronated during uptake. Glucuronides may
be metabolized, or stored or set free as aglycones by tissue-
specific glucuronidases; thus, plasma concentration may
not always be a good measure of bioavailability (Seelinger
et al. 2008). Most flavonoids, except catechins, exist in
nature as glycosides. Moreover, at least quercetin gluco-
sides were absorbed better than the aglycone quercetin-b-
glucoside (Hollman and Katan 1998). Finally, supple-
mentation of the diet should more appropriately use fla-
vonoid glycosides instead of aglycones. However, this has
been questioned by other researchers (Manach et al. 1997).
The role of flavonoid glycosylation in facilitating absorp-
tion is questioned by the fact that catechin, which is not
glycosylated in nature, is absorbed relatively efficiently
(Okushio et al. 1996). Because the half-lives of conjugated
Fig. 1 Subclasses of flavonoids
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flavonoids are rather long (23–28 h) (Young et al. 1999),
accumulation may occur with regular intakes, which may
in turn result in sufficiently active flavonoid concentrations
(Nijeveldt et al. 2001). Flavanoid bioavailability and the
mechanism by which flavonoids are absorbed from intes-
tine and metabolized via microbial catabolism, conjugation
in liver and enterocytes have been studied by a number of
workers (Hollman and Katan 1999; Scalbert and Wil-
liamson 2000, Hollman 2004; Passamonti et al. 2009).
Studies in human and animals have indicated that some
PPT (for example cinnamate conjugates, flavanols, quer-
cetin glucosides) can be absorbed in the small intestine
(Olthof et al. 2000, 2003; Nardini et al. 2002; Cermak et al.
2004) while quercetin, quercetin galactoside, rutin, na-
ringenin-7-glucoside and many others are not. Mechanism
of absorption has not been completely elucidated while the
membrane transport of flavonoids is a fundamental part of
their bioavailability in both plant and animal organisms,
and current knowledge suggests the involvement of both
ATP-dependent pumps and ATP-independent transporters
(Passamonti et al. 2009).
Depending on PPT subclass, only 5–10 % of amount
consumed is absorbed in small intestine and major part of
that absorbed in the duodenum enters the circulation as
methylated, sulfate-conjugated, glucuronide-conjugated
and glycine-conjugated forms (Kroon et al. 2004). The rest
90–95 % of total PPT ingested plus any mammalian glu-
curonide excreted through bile pass to the colon where they
are metabolized by gut microflora. Transformations may be
extensive, and include the removal of sugars, removal of
phenolic hydroxyls, fission of aromatic rings, hydrogena-
tion, and metabolism to carbon dioxide, possibly via oxa-
loacetate (Walle et al. 2001). A substantial range of
microbial metabolites has been identified, including phe-
nols and aromatic acids, phenolic acids, or lactones pos-
sessing 0, 1, or 2 phenolic hydroxyls and up to five carbons
in the side chain (Clifford and Brown 2006). The elimi-
nation half-lives are very variable, ranging from as low as
1 h (Meng et al. 2001) to values in excess of 20 h (Olthof
et al. 2003).
Flavonoid as anti-cancer agents
Epidemiological studies
A huge number of epidemiological studies have been
conducted to prove the protective effect of flavonoids
against cancer. Increased consumption of lignans and
greater plasma concentrations of their metabolites have
been linked with reduced incidence of estrogen-related
cancers in some (Pietinen et al. 2001; Dai et al. 2002;
Boccardo et al. 2004; McCann et al. 2004) but not all
studies, (Kilkkinen et al. 2004; Zeleniuch-Jacquotte et al.
2004) and a prospective study was equivocal (den Ton-
kelaar et al. 2001). It has been suggested that this incon-
sistency might have a genetic basis (McCann et al. 2002).
Increased consumption of isoflavones has also been asso-
ciated with decreased risk of estrogen-related cancers and
vascular diseases (Arai et al. 2000; Birt et al. 2001). Data
Table 1 Different groups of flavonoids and their dietary sources
Flavonoid
group
Subgroup Major sources Anti-cancer properties





Chocolate, green and black tea,
beans, cherry, strawberries, cocoa,
apple
Human oral, rectal and prostate cancer
Flavones Apigenin, chrysin, luteolin Parsley, celery, capsicum, pepper,
broccoli
Lung cancer, leukemia, stomach, colon,
thyroid, oral and laryngeal cancer, breast
cancerFlavonol: kaempherol, myricetin,
quercetin, rutin
Brussel sprouts, apples, onion, curly
kale, leek, beans, cherries
Flavanones: eriodictyol, hesperitin,
naringenin
Orange juice, grape fruit juice,
lemon juice
Flavanonols: taxifolin Milk thistle, red onion, acai palm,
Siberian larch tree
Anthocyanidins Cyanidin, delphinidin, malvidin,
petunidin, peonidin, pelargonidin
Aubergine, black berries, black
currant, blue berries
Colorectal cancer
Isoflavonoids Isoflavones: daidzein, genistein, glycitein
Isoflavane: equol
Soy flour, soy beans, soy milk, miso,
tempeh, beer
Metabolized from daidzein by
intestinal bacteria
Breast cancer, prostate cancer, colon, kidney
and thyroid cancer
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from four cohort studies and six case–control studies,
which have examined associations of flavonoid intake with
cancer risk revealed that flavonoids, especially quercetin,
may reduce the risk of lung cancer in two studies but a non-
significant increased risk in a third study. High versus low
quercetin and kaempferol intakes were associated with 40
and 50 % reduction in risk, respectively, for stomach
cancer. There was no statistically significant association of
any flavonoids with either bladder cancer or breast cancer
risk (Neuhouser 2004). In a network of multicentric Italian
case–control studies including about 10,000 incident, his-
tologically confirmed cases of selected cancers and over
16,000 controls, the association of flavonoids, proantho-
cyanidins and cancer risk was evaluated by Rossi et al.
(2010). It was found that total flavonoids, flavanones, and
flavonols were inversely related to oral and laryngeal
cancers (ORs, respectively, 0.56 and 0.60 for total flavo-
noids; 0.51 and 0.60 for flavanones; and 0.62 and 0.32 for
flavonols). Flavonols were also inversely related to
laryngeal cancer (OR 0.64), whereas flavanones were
inversely related to esophageal cancer (OR 0.38). A
reduced risk of colorectal cancer was found for high intake
of anthocyanidins (OR 0.67), flavonols (OR 0.64), flavones
(OR 0.78), and isoflavones (OR 0.76). Inverse relations
with breast cancer were found for flavones (OR 0.81) and
flavonols (OR 0.80). Flavonols (OR 0.63) and isoflavones
(OR 0.51) were inversely associated to ovarian cancer,
whereas flavonols (OR 0.69) and flavones (OR 0.68) were
inversely associated to renal cancer. No association
between flavonoids and prostate cancer emerged, whereas
inverse association was found between proanthocyanidins
and colorectal cancer. These associations appeared stronger
for proanthocyanidins with a higher degree of polymeri-
zation (Rossi et al. 2010).
In the European Prospective Investigation into Cancer
and Nutrition study (Nothlings et al. 2008), the intake of
vegetables, legumes, and fruit was significantly associated
with reduced risks of CVD mortality and mortality due to
Fig. 2 Pathway of biosynthesis
of flavonoids
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non-CVD/non-cancer causes [RR 0.88 (95 % CI
0.81–0.95) and 0.90 (0.82–0.99), respectively] in a diabetic
population comprising [10,000 individuals. High urinary
excretion of both equol and enterolactone (mammalian
metabolite of plant lignans) has been found to be associated
with a significant decrease in breast cancer risk in an epi-
demiological case–control study in breast cancer patients
(Ingram et al. 1997). Although this could suggest the
possible importance of isoflavonoid and lignan metabolism
in decreased breast cancer risk, the phytoestrogen excretion
observed may just be a marker of dietary differences
(Barnes 1998). Knekt and co-workers also estimated that
men with higher quercetin intake had a lower lung cancer
incidence, and men with higher myricetin intakes had a
lower prostate cancer risk (Knekt et al. 2002).
The intake of flavonoids is not inversely related with
bladder cancer or breast cancer risk in some of the studies
(Garcia-Closas et al. 1999; Peterson et al. 2003). Quercetin
has been reported to prevent renal cell cancer among male
smokers (Wilson et al. 2009). A case–control study con-
ducted between 1994 and 2002 in four Italian areas to study
the relation between major flavonoid classes and renal cell
carcinoma by Bosetti et al. 2007 revealed that flavonols
and flavones were inversely related to the risk of renal
cancer. A cohort of 34,651 postmenopausal cancer-free
women revealed inverse relation between catechin intake
and rectal cancer (Arts et al. 2002).
Population-based case–control studies carried out sepa-
rately in Hawaii, Uruguay and Spain suggested an inverse
association between different cancers (oral cavity, pharynx,
larynx and esophagus, lungs, stomach) and total intake of
flavonoids, beta-carotene and vitamin E (Le Marchand et al.
2000; Stefani et al. 1999a, b; Garcia-Closas et al. 1999).
Inverse association of cholangiocarcinomas (CAC) with
flavan-3-ols, anthocyanidins and total flavonoids has been
reported and flavones may be inversely associated with
hepatocellular carcinoma cells (HCC) risk (Lagiou et al.
2008). A statistically significant association between high-
est flavonoid intake and reduced risk of developing lung
cancer has been reported whereby an increase in flavonoid
intake of 20 mg/day was associated with a 10 % decreased
risk of developing lung cancer (Tang et al. 2009).
The studies on tea, flavonoids and lung cancer risk
indicated a small beneficial association, particularly among
never-smokers. More well-designed cohort studies are
needed to strengthen the evidence on effects of long-term
exposure to physiological doses of dietary flavonoids (Arts
2008). Consumption of soy foods rich in isoflavones has
been weakly associated with reduced colon and prostate
cancer (Adlercreutz 2002; Guo et al. 2004; Holzbeierlein
et al. 2005; Goetzl et al. 2007). A protective effect of
flavonoids in association with vitamin C has been shown
on esophageal cancer using data from case–control study
conducted in northern Italy (Rossi et al. 2007). Flavonoid-
rich diet may decrease pancreatic cancer risk in male
smokers not consuming supplemental alpha-tocopherol and
beta-carotene (Bobe 2008).
In vitro studies
Isoflavonoids have biphasic effects on the proliferation of
breast cancer cells in culture; at concentrations [5 mM,
genistein exhibits a concentration-dependent ability to
inhibit both growth factor-stimulated and estrogen-stimu-
lated (reversed by 17b-estradiol) cell proliferation (So et al.
1997). Although genistein is a much better ligand for ERb
than for the ERa (20-fold higher binding affinity) (Kuiper
et al. 1997), it can also act as an estrogen agonist via both
ERa and ERb in some test systems (Kuiper et al. 1998;
Mueller et al. 2004). Furthermore, although genistein binds
to the ligand-binding domain of ERb in a manner similar to
that observed for 17b-estradiol, in the ERb–genistein
complex the AF-2 helix (H12) does not adopt the normal
agonist type position, but instead takes up a similar ori-
entation to that induced by ER antagonists such as ra-
loxifene (Pike et al. 1999). This suboptimal alignment of
the transactivation helix is in keeping with the reported
partial agonist activity of genistein via ERb in human
kidney cell (Barkhem et al. 1998).
Anti-cancer activity of methanolic flower extract of
Tecoma stans (METS) was evaluated by both in vitro (Vero
and Hep 2 cell lines) and in vivo (using Ehrlich ascites
carcinoma tumor model) methods and compared with
5-flurouracil. A significant dose-dependent anti-tumor
activity was indicated (Kameshwaran et al. 2012). Enri-
ched ginger extract exhibited higher anti-cancer activity on
MCF-7 breast cancer cell lines with IC 50 value 34.8 and
25.7 lg/ml for two varieties. IC50 values for MDA-MB-
231 were 32.5 and 30.2 lg/ml for rhizome extract of two
varieties (Rahman et al. 2011). Luteolin-7-methyl ether
isolated from leaves of Blumea balsemifera showed strong
cytotoxicity against human lung cancer cell lines (NCI-
H187) with IC 50 of 1.29 lg/ml and moderate toxicity
against oral cavity cancer cell lines (KB) with IC 50 of
17.83 lg/ml (Saewan et al. 2011).
In vitro and in vivo studies on anti-cancer activity of
flavonoids isolated from a herbal formulation revealed IC
50 of 24.948, 31.569 and 6.923 lg/ml, respectively, on
three cancer cell lines MCF-7, Hep G-2 and ES-2 with
dose-dependent inhibitory effect on hepatocellular carci-
noma in mice (Liu et al. 2011). Broccolini leaf flavonoids
(BLF) possess a dose-dependent anti-proliferative effects
on four human cancer cell lines (SW480, HepG2, Hela, and
A549) and apoptosis induction activity on SW480 cell line.
Thus, the hybrid species Broccolini could be considered as
a functional vegetable with potential in assisting for the
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treatment of four human cancers examined (Wang and
Zhang 2012).
Apigenin inhibited skin papillomas and showed the
tendency to decrease conversion of papillomas to carcino-
mas (Wei et al. 1990). Luteolin has been shown to penetrate
into human skin, making it also a candidate for the pre-
vention and treatment of skin cancer (Seelinger et al. 2008).
Seufi et al. (2009) demonstrated that preventive effect of
quercetin on hepato carcinomas in rats by RAPD-PCR,
whereby, it was proved that quercitin exerted a preventive
effect via decreased oxidative stress and decreased anti-
oxidant activity. Dietary proanthocyanidins mostly present
in apples, pears and pulses has been suggested to reduce the
risk of pancreatic cancer by 25 % (Rossi et al. 2010).
Ethanolic extract of propolis has been found to inhibit
urinary bladder transitional cell carcinoma (TCC) cell
proliferation with no cytotoxic effect on normal epithelial
cells (Orsˇolic´ et al. 2010). Genistein inhibited the expres-
sion of micro-RNA 21 in A-498 (RCC) cells and in the
tumors formed after injecting genistein treated A-498 cells
in nude mice besides inhibiting tumor formation (Zaman
et al. 2012).
Kaempferol, a dietary flavonoid is effective in reducing
vascular endothelial growth factor (VEGF) expression in
ovarian cancer cells. It enhances the effect of cisplatin
through downregulation of cMyc in promoting apoptosis of
ovarian cancer cells (Luo et al. 2010). The growth of U14
cervical cancer could be inhibited by Scutellaria baical-
ensis total flavonoids (STF), the cell proliferation inhibited
by arresting cell cycle and cell apoptosis induced by reg-
ulating the expression of Bax and Bcl-2 gene by treatment
of STF (Peng et al. 2011). Some of the Indian medicinal
plants like Ashwagandha, Curcumin, Lithosprmum radix,
green tea, Chinese herb Astragalus and Japanese herb Ju-
zen-Taiho-To have been reported to be effective against
various cell lines of lung cancers (Ravichandiran et al.
2011). A comparison of cytotoxic effect of 11 flavonoids
on chronic myeloid leukemia K562 cells and peripheral
blood mononuclear cells indicated that baicalein and my-
ricetin had a specific cytotoxic effect on leukemia cells
(Romanouskaya and Grinev 2009).
Apoptotic activity of 22 flavonoids and related com-
pounds in leukemic U937 cells were tested by Monasterio
et al. (2004). They reported that flavones but none of the
isoflavones induced the apoptotic cell death as determined
by reduction in cell viability, flow cytometery and oligo-
nucleosomal DNA fragmentation. The molecular conse-
quences of apigenin treatment in myeloid and erythroid
subtypes reveal the blocked proliferation of both cell lines
through cell cycle arrest in different phases. JAK/STAT
was one of the major target of apigenin but at the same
time apigenin reduced susceptibility toward the commonly
used therapeutic agent vincristine (Ruela-de-Sousa et al.
2010). A newly synthesized flavonoid III-10 could express
anti-cancer effect on human U937 leukemia cell line
through differentiation induction. The differentiation-rela-
ted proteins phospholipids scramblase 1 (PLSCR1) and
promyelocytic protein (PML) were upregulated after III-10
treatment through activation of protein kinase Cd (Qin
et al. 2012). Quercetin inhibited thyroid cell growth
in association with inhibition of insulin-modulated-PI3-
Kinase-AKT kinase activity. It also decreased TSH-mod-
ulated RNA level of NIS (sodium iodide sympoter) gene
and thereby suggested to be a novel disrupter of thyroid
function which has potential uses in thyroid cancers (Gi-
uliani et al. 2008). Chrysin inhibited proliferation of HTH 7
and KAT 18 (anaplastic thyroid cancer cell lines) in a dose
and time-dependent manner. A significant increase in
cleaved caspase-3, cleaved polyADP ribose polymerase
(PARP) along with a decrease in cyclin D1, Mcl-1 and
XIAP was observed (Phan et al. 2011). BNF (b-napthof-
lavone) showed a moderate anti-proliferative activity in
WHCO-6 cells and a weak activity in WHCO-1 cells. It
resulted in differential expression of CYP1A1, CYP1A2
and CYP1B1 (Molepo 2010).
In vivo studies
In vivo studies using animal models have suggested the
protective effect of flavonoids against initiation as well as
tumor progression. Animal model studies have provided the
initial experimental evidence that soy can prevent breast
cancer (Barnes 1998; Messina et al. 1994). Fermented soy
milk (rich in genistein and daidzein), given to rats at
7 weeks of age, inhibited mammary tumorigenesis induced
by PhIP (2-amino-1-methyl-6-phenylimidazo [4,5-b] pyri-
dine (Ohta et al. 2000). In syngenetic mice, i.p. adminis-
tration of quercetin and apigenin inhibited growth and
metastatic potential of melanoma cell (B16-BL6) along
with significant decrease in their invasion in vitro (Caltag-
irone et al. 2000). A polymethoxy flavonoid, nobiletin,
inhibited the tumor-invasive activity of human fibrosar-
coma HT-1080 cells in the Matrigel model through sup-
pressing the expression of metalloproteases and augmenting
of production of tissue inhibitors of metalloproteinases in
tumor cells (Sato et al. 2002). Furthermore, injection of
prepubertal rats with genistein (500 mg/g body weight) or
estradiol benzoate (500 ng/g body weight) on days 16, 18,
and 20 showed that both treatments resulted in significantly
increased mammary gland terminal end buds and increased
ductal branching compared to controls, indicating an ER-
dependent action of genistein in mammary gland prolifer-
ation and differentiation, which could be protective against
mammary cancer (Cotroneo et al. 2002). Overall, these
results indicate that genistein has very complex effects on
carcinogen-induced mammary cancer in the rat model and
3 Biotech (2013) 3:439–459 445
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great care is required in interpreting these results and
drawing parallels with human breast cancer. Equol has been
found to be a novel anti-androgen that inhibits prostate
growth and hormone feedback in rat studies (Lund et al.
2004). In nude mice with xenografted tumors using HAK-
1B hepatoma cells, luteolin significantly inhibited the
growth of the tumors in a dosage-dependent manner by
targetting STAT3 through dual pathways—the ubiquitin-
dependent degradation in Tyr705-phosphorylated STAT3
and the gradual downregulation in Ser727-phosphorylated
STAT3 through inactivation of CDK5, thereby triggering
apoptosis via upregulation in Fas/CD95 (Selvendiran et al.
2006). A flavonoid rich fraction (Fr-6) and a more purified
proanthocyanidin (PAC) were isolated from cranberry and
both fractions are found to slow the growth of explant tumor
U87 in vivo, PAC inhibited growth of HT-29 and DU145
explants (p \ 0.05), inducing complete regression of two
DU145 tumor explants (Ferguson et al. 2004). A covalent
conjugate of artemisinin (flavonoid from Artemisia annua)
and transferrin (ART-Tf), an iron transport protein in
human, are actively taken up by cancer cells through the
transferrin receptor (TfR)-mediated endocytosis pathway,
and show significantly higher anti-cancer activity than
unconjugated artemisinin (Lai et al. 2005; Nakase et al.
2009). Like ART-Tf, artemisinin–peptide conjugates that
are designed to target TfR also showed highly potent and
selective anti-cancer activities (Oh et al. 2009). Although
the generation of free radicals originating from the reaction
of artemisinin with molecular iron is mentioned as one of
the main mechanism for its anti-cancer activity, there are
other mechanisms, crucial for cancer proliferation and
survival that are affected by artemisinins. These mecha-
nisms have been described in a current review (Firestone
and Sundar 2009; Ferreira et al. 2010). Mammographic
breast density can be used as biomarker of estrogenic or
anti-estrogenic effects of a particular treatment on breast
tissue (Atkinson et al. 2004). Consumption of a dietary
supplement that provided red clover-derived isoflavones
(26 mg biochanin A, 16 mg formononetin, 1 mg genistein,
and 0.5 mg daidzein) for 12 months did not increase
mammographic breast density in postmenopausal women,
suggesting neither estrogenic nor anti-estrogenic effects, of
this supplement at the dose given, on the breast (Atkinson
et al. 2004). Honeybee propolis and its polyphenolics
exerted an anti-metastatic anti-tumor effect in mice and rats
and considerable cytotoxicity without cross resistance in
both wild-type and chemoresistant human tumor cell lines
suggesting these to be potent adjunct to chemotherapy and
radiotherapy in treatment of cancers (Orsˇolic´ et al. 2010).
Colon cancer risk is influenced by estrogen exposure;
studies with estrogen receptor a knockout mice indicate that
it may be independent of estrogen receptor a (Guo et al.
2004). Furthermore, in vivo studies in male rats have shown
that genistein decreases the amount of EGF receptor present
in the prostate, indicating that the observed decrease in
tyrosine phosphorylation may be only a secondary effect of
the influence of genistein on the expression or turnover of
EGF receptor (Dalu et al. 1998). Luteolin can delay or block
the development of cancer cells in vitro and in vivo by
protection from carcinogenic stimuli, by inhibition of tumor
cell proliferation, by induction of cell cycle arrest and by
induction of apoptosis via intrinsic and extrinsic signaling
pathways. When compared to other flavonoids, luteolin was
usually among the most effective ones, inhibiting tumor cell
proliferation with IC50 values between 3 and 50 lM
in vitro and in vivo by 5–10 mg/kg i.p., intragastric appli-
cation of 0.1–0.3 mg/kg/d, or as food additive in concen-
trations of 50–200 ppm (Seelinger et al. 2008).
Molecular mechanism of anti-cancer effect
Flavonoids have been very often pointed out as in vitro
enzyme inhibitors and ligands of receptors involved in
signal transduction (Middleton and Kandaswami 1994;
Havsteen 2002; Williams et al. 2004; Brown et al. 2007;
Balasuriya and Rupasinghe 2011). So these flavonoid–
protein interactions together with their anti-oxidant prop-
erties are the key features for their potential health benefits.
Furthermore, some effects may be a result of a combination
of radical scavenging and interaction with enzyme func-
tions. The phenolic nucleus is a structural unit that is
favorable to molecular (non-covalent) interactions with
proteins.
These interactions can be either Vander wall or elec-
trostatic interactions. In former type, the non-polar polar-
izable aromatic ring can develop strong dispersion
interactions with non-polar amino acid residues followed
by simultaneous release of water; while in later type,
H-bonding is the most important electrostatic interaction.
Flavanoid–protein redox reactions and oxidative covalent
coupling may result fom one-or two-electron oxidation of
the flavonoid brought about by autooxidation, scavanging
of reactive oxygen species and enzymatic oxidation. For
some conformationally open proteins (e.g. salivary pro-
teins), binding constants are quite low with polyphenols but
polymerization and condensation of these polyphenols
produces an increase in affinity (Kurisawa et al. 2003; Kim
et al. 2004). It can be due to unspecific binding along an
extended protein chain or at the surface of globular proteins
(Haslam 1996; Spencer et al. 1988; Xi and Guo 2008).
Inhibition of PKs
Phosphorylation of proteins at OH groups of serine, thre-
onine, and tyrosine residues is an important mechanism of
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intracellular signal transduction involved in various cellu-
lar responses including the regulation of cell growth and
proliferation (Birt et al. 2001; Bridges 2001). The reaction
makes use of ATP as a phosphate donor and is catalyzed by
protein kinases. For instance, growth factor hormones bind
to extracellular domains of large transmembrane receptors
that display a tyrosine kinase moiety in their intracellular
portion. As a consequence of hormone–receptor binding,
the receptor dimerizes and becomes active in the phos-
phorylation of proteins close to the membrane, thereby
triggering a large number of signaling pathways them-
selves involving other PKs, such as PKC, a Ser/Thr PK,
and mitogen-activated PKs (MAPKs). On the other hand,
each phase of the cell cycle, during which the DNA is
replicated and the chromosomes built and then separated, is
characterized by intense bursts of phosphorylation con-
trolled by highly regulated kinases called cyclin-dependent
kinases (CDKs). A possible mechanism for the potential
anti-carcinogenic effects of flavonoids could be their abil-
ity to inhibit various PKs, thereby inhibiting signal trans-
duction event of cell proliferation.
The isoflavone genistein has been shown to inhibit the
epidermal growth factor (EGF) receptor in the submi-
cromolar range by competing with ATP for its binding site
(Rudrabhatla and Rajasekharan 2005; Akiyama et al.
1987). Similarly, butein (20,3,4,40-tetrahydroxychalcone)
appears as a specific inhibitor of tyrosine kinases (IC50 for
EGF receptor65 mM) acting competitively to ATP and
non-competitively to the phosphate acceptor and having no
affinity for Ser/Thr PKs such as PKC and the cAMP-
dependent PKA (Yang et al. 1998, 2006).
Recently, PKC was shown to be efficiently inhibited by
flavones and flavonols having a 30,40-dihydroxy substitu-
tion on the B ring (efficient concentrations 50 in the range
1–10 mM) (Agullo et al. 1997; Gamet-Payrastre et al.
1999) phosphoinositide 3-kinase (PI3-K), a lipid kinase
catalyzing phosphorylation of inositol lipids at the D3
position of the inositol ring to form new intracellular lipid
second messengers (Gamet-Payrastre et al. 1999) is also
inhibited by flavonoids.
Consistently, studies with intact cells have shown that
various flavonoids can cause cell cycle arrest in correlation
to their ability to inhibit CDKs (Zi et al.1998; Casagrande
and Darbon 2001). Flavonoids can also modulate the
activity of MAPKs as a possible mechanism for their
potential anti-neurodegenerative action (Schroeter et al.
2001, 2002) and protection against autoimmune, allergic,
and cardiovascular diseases (Yoshizumi et al. 2002; Ahn
et al. 2004). For instance, investigations on intact antigen-
presenting dendritic cells have shown that the MAP kinases
involved in cell maturation (ERK, p38 kinase, JNK) can be
activated by bacterial lipopolysaccharide and that this
activation is strongly inhibited by pretreatment of the cells
by EGCG.61 However, no evidence is provided that the
mechanism actually proceeds via direct EGCG–MAPK
inhibition.
Inhibition of prooxidant enzymes
Formation of reactive oxygen species (ROS) is a major step
in the tumor promotion and progression stages. The
involvement of ROS in tumor progression has been dem-
onstrated in human cells. NADPH oxidase I (NOX 1), an
enzyme that produces superoxide is overexpressed in colon
and prostate cancer cell lines (Fukuyama et al. 2005; Lim
et al. 2005), while its downregulation reverses tumor
growth (Arnold et al. 2007). ROS play important role in
DNA damaging and mutagenic signaling (Poli et al. 2004;
Valko et al. 2004). ROS act as secondary messenger in
several pathways that lead to increase in cell proliferation,
resistance to apoptosis, activation of proto-oncogenes such
as cFOS, cJUN and cMyc. In human hepatoma cells, ROS
modulate the expression of cFOS and cJUN through PKB
pathway (Liu et al. 2002).
Lipoxygenases (LOX), cycloxygenases (COXs), and
xanthine oxidase (XO) are metalloenzymes whose catalytic
cycle involves ROS such as lipid peroxyl radicals, super-
oxide, and hydrogen peroxide. LOXs and COXs catalyze
important steps in the biosynthesis of leucotrienes and
prostaglandins from arachidonic acid, which is an impor-
tant cascade in the development of inflammatory responses.
XO catalyzes the ultimate step in purine biosynthesis, i.e.,
the conversion of xanthine into uric acid. XO inhibition is
an important issue in the treatment of gout. Flavonoids may
exert part of their anti-oxidant and anti-inflammatory
activities via direct inhibition of these prooxidant enzymes
(LOXs, COXs, and XO). Similarly, flavonoids can inhibit
ornithine decarboxylase (rate-limiting enzyme in poly-
amine biosynthesis) induced by tumor promoters, and
thereby inhibiting proliferation. Typically, interpretation of
the inhibition studies is complicated because of the possi-
ble combination of distinct inhibition mechanisms: for-
mation of non-covalent enzyme-inhibitor complexes, direct
scavenging by flavonoid anti-oxidants of ROS inside or
outside the catalytic pocket (with simultaneous oxidation
of the flavonoids), chelation of the enzyme metal centers
by the flavonoids, and enzyme inactivation by reactive a-
ryloxyl radicals, quinones, or quinonoid compounds pro-
duced upon flavonoid oxidation that may eventually form
covalent adducts with the enzyme (Olivier and Claire 2005;
Sandhar et al. 2011).
Modulate the metabolism of carcinogen
Activation of a procarcinogen to carcinogen is an important
step in carcinogenesis and can be modulated by flavonoids.
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Flavonoids can exert their effect by two possible mecha-
nisms. Firstly, by interacting with phase 1 enzymes
(CyP450) that are involved in metabolic activation of pro-
carcinogens. Second mode of action can be the detoxifi-
cation and elimination of carcinogens via induction of
phase II enzymes such as UDP-glucuronyl transferase,
quinone reductase and glutathione S-transferase.
These heme-containing cytochrome P450 (CYP) mon-
ooxygenases include several isoforms (CYP 1A1, 1A2,
1B1, 3A4, 3A5, etc.) with different tissue distributions and
play a key role in the metabolism of endogenous substrates
(e.g., steroids) and xenobiotics (food components, drugs,
carcinogens, pollutants) (Anzenbacher and Anzenbache-
rova´ 2011; Hodek et al. 2002; Ahmad and Mukhtar 2004).
Indeed, CYPs are responsible for the conversion of some
procarcinogens (e.g., polyaromatic hydrocarbons or PAHs)
into carcinogens (e.g., PAH epoxides). Cytochrome P450
enzymes are a good example of proteins whose function
can be regulated by flavonoids via such diverse mecha-
nisms (Hodek et al. 2002, 2009).
CYP–flavonoid interactions are a good example of the
multiple ways flavonoids can affect enzymatic activities,
i.e., from the regulation of gene expression to direct
binding to the processed enzymes. Flavonoids can induce,
or eventually inhibit, the biosynthesis of CYP 1A1 via
interactions with the aryl hydrocarbon receptor (AhR), a
cytosolic protein that, once activated by a ligand, translo-
cates to the nucleus and, in association with the AhR
translocator, forms a transcription factor for CYP 1A1. For
instance, in human breast cancer cells, quercetin binds to
AhR as an agonist and stimulates gene expression for CYP
1A1 with a parallel increase in CYP 1A1-mediated O-
deethylation of 7-ethoxyresorufin (Ciolino et al. 1999).
This process is strikingly dependent on the hydroxylation
pattern of the B ring since kaempferol (30-deoxyquercetin)
binds AhR as an antagonist (no subsequent activation of
CYP 1A1). It is also highly dependent on the cell type
since, in hepatic cells, quercetin binds to AhR as an
antagonist, thereby inhibiting gene expression for CYP
1A1 and benzo[a]pyrene activation (Kang et al. 1999). This
provides a possible mechanism for the anti-cancer activity
of quercetin. Flavonoids, especially flavones and flavonols,
also directly bind to several CYP isoforms (1A1, 1A2, 1B1,
3A4) involved in xenobiotics metabolism and inhibit
enzyme activity. Structure–activity relationships (Doostdar
et al. 2000) show rather high isoform selectivities
depending on the flavonoid substitution pattern and con-
trasted inhibition mechanisms. Finally, flavonoids are also
able to inhibit CYP19 or aromatase, an enzyme catalyzing
a three-step oxidation sequence resulting in aromatization
of the A ring of male steroid hormones (androgens) to yield
estrogens. Together with flavonoid–estrogen receptor
binding, this process could be relevant to the prevention of
hormone-dependent breast cancer by flavonoids (Brueg-
gemeier et al. 2001).
Interestingly, 17b-hydroxysteroid dehydrogenase, another
redox enzyme involved in steroid metabolism, is also
strongly inhibited by 7-hydroxyflavonoids (Le Bail et al.
1998). For instance, the flavone apigenin is more potent
at inhibiting 17b-hydroxysteroid dehydrogenase (IC50
0.3 mM) than aromatase (IC50 2.9 mM) and the iso-
flavone genistein, which is only a weak aromatase inhibi-
tor, inhibits 17b-hydroxysteroid dehydrogenase with an
IC50 of 1 mM. The flavonols quercetin, kaempferol,
myricetin, the flavone apigenin, and the biflavone biapi-
genin were also reported to inhibit CYP3A4 activity at low
micromolar concentrations in human liver microsomes
(von Moltke et al. 2004).
Xenobiotics, drugs and flavonoids follow the same
course of metabolism. As these compounds are hydro-
phobic in nature, so the first step involving the conjugation
of these drugs to increase their hydrophilicity is a key step
in their metabolism. This step is performed by the above
mentioned phase-II enzymes. Flavonoids have been dem-
onstrated to activate these enzymes and thereby increase
detoxification and elimination of carcinogens from the
body. UDPglucuronosyltransferases (UGT) use UDP-glu-
curonic acid as a cosubstrate and transfer glucuronic acid to
available substrates thereby making them more water sol-
uble and facilitating their excretion in the urine or bile.
Similarly, sulfotransferases (SULT) catalyze the transfer of
a sulfonate group, glutathione S-transferases (GST) transfer
glutathione and N-acetyltransferases transfer acetyl moiety
to an appropriate substrate. It has been shown that all these
phase II enzymes are affected by flavonoids in cell and
animal models.
An increase in mRNA levels, protein expression and
enzyme activity of UGT isoform 1A1 has been reported in
human Hep G2 cells and human colon carcinoma cells by
chrysin, apigenin, baicalein, diosmetin, quercetin and ka-
empferol (Galijatovic et al. 2001; Walle and Walle 2002;
Sugatani et al. 2004). van der Logt et al. 2003 reported an
increase in UGT activity in intestine and liver by feeding
rats on a diet containing 1 % wt/wt quercetin and 0.5 % wt/
wt flavones. Quercetin significantly increased UGT1A1
mRNA in shed enterocytes on in vivo perfusion of human
jejunam and in Caco-2 cells (Petri et al. 2003). A number
of flavonoids including fisetin, galangin, quercetin, ka-
empferol, and genistein represent potent non-competitive
inhibitors of sulfotransferase 1A1 (or P-PST); this may
represent an important mechanism for the chemopreven-
tion of sulfation-induced carcinogenesis (Moon et al.
2006). Dietary intake of citrus limonoids (Perez et al. 2010)
may provide a protective effect against the onset of various
cancers by inducing the activity of certain phase II detox-
ifying enzymes [glutathione S-transferase and NAD(P)H:
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quinone reductase] in specific organs. Johnson et al. (2009)
analyzed the ability of eriodictyol to activate Nrf2 and
induce the phase II proteins, heme-oxygenase (HO-1),
NAD(P)H: quinone oxidoreductase 1 (NQO-1), and the
cellular anti-oxidant glutathione, GSH. They have shown
that ARPE-19 cells that overexpress HO-1 or NQO-1 were
more resistant to oxidative stress-induced cell death than
control cells. Cermak (2008) reviewed flavonoids as potent
inhibitors of cytosolic SULT isoforms. Quercetin inhibited
sulfation of 4-nitrophenol and of several drugs including
salbutamol, minoxidil, paracetamol, apomorphine in
human liver cytosol (De Santi et al. 2002; Marchetti et al.
2001; Vietri et al. 2002). Quercetin significantly affected
the activity of hepatic GST, whereas dietary catechin sig-
nificantly changed NAD(P)H quinone oxidoreductase-1
activity (26 %) in rats. Changes in GST and NAD(P)H
quinone oxidoreductase-1 activity were partly reflected on
mRNA levels (Wiegand et al. 2009).
Inhibition of multidrug resistance
Cancer cells typically overexpress P-glucoprotein (Pgp) or
multidrug resistance associated protein (MRP) which is
ATP-dependent transmembrane transporters capable of
expelling a wide variety of chemically unrelated drugs used
in cancer therapy at the expense of ATP hydrolysis. This
phenomenon is known as multidrug resistance (MDR) and
inhibition of MDR, to prevent drug efflux has potential
clinical application during cancer therapy.
Quercetin was shown to efficiently inhibit the Pgp-
mediated drug efflux by inhibiting the overexpression of
human MDR1 gene (Kioka et al. 1992) and by inhibiting
the ATPase activity required for transport (Shapiro and
Ling 1997). From investigations using a soluble cytosolic
portion of mouse Pgp, which includes the nucleotide- and
drug-binding domains, it was possible to monitor flavonoid
binding by fluorescence as well as its influence on ATP
binding and the efflux of the anti-cancer steroid drug RU
486 (Conseil et al. 1998). Flavones (aglycones) bearing OH
groups at positions 3 and 5 come up as efficient mouse Pgp
ligands with apparent dissociation constants lower than
10 mM. By contrast, the quercetin glycoside rutin, the
flavanone naringenin, and the isoflavone genistein have
low affinity for Pgp. Interestingly, flavones and flavonols
behave as bifunctional inhibitors whose binding site over-
lap the vicinal binding sites for both ATP and RU 486.
Those trends were confirmed using a cytosolic portion of
Pgp from the parasite Leishmania tropica (Perez-Victoria
et al. 1999). Flavonoids have been reported to inhibit
ATPase activity, nucleotide hydrolysis and energy-depen-
dent drug interaction with transporter enriched membranes
(Di Pietro et al. 2002). This unique property of reversal of
MDR has been found to enhance doxorubin (DOX)-
induced anti-tumor activity by increasing the DOX con-
centration at target site (Blagosklonny 2001). To study that
how epicatechin gallate, epigallocatechin gallate, genistein,
genistin, naringenin, naringin, quercetin and xanthohumol
will modulate cellular uptake and permeability [P(e)] of
multidrug-resistant substrates, cyclosporin A (CSA) and
digoxin, across Caco-2 and MDCKII-MDR1 cell-transport
models, uptake experiments were perfomed with and
without flavonids. Aglycone flavonoids reduced the P(e) of
CSA to a greater extent than that of digoxin, suggesting
that transport mechanism of CSA can be different from
digoxin (Rodriguez-Proteau et al. 2006). Ofer et al. (2006)
compared the potency of quercetin, isoquercitin, spiraeo-
side, rutin, kaempferol, naringenin, naringin and hesperetin
to inhibit the transport through P-gp transporters (substrate
3H-talinolol) and OCT (substrate 14C-TEA) of Caco-2 cells
and LLC-PK 1 cells, respectively. Six of the investigated
flavonoids reduced the secretory flux of talinolol across
Caco-2 cells but none of the selected flavonoids was able to
replace 3H-talinolol from its binding to P-gp. This might be
due to an interaction with P-gp, but apparently not via
competition at the talinolol binding site of P-gp. The
investigated flavonoids did show potency to inhibit OCT-
mediated transport (IC50-values: quercetin \ kaempfer-
ol  naringenin \ isoquercitrin \ spiraeoside  rutin \
hesperetin \ naringin) may be by the inhibition of mem-
bers of the OCT family.
This flavonoid–ABC-transporter interaction could be
beneficial for poorly absorbed drugs but could also result in
severe drug intoxication, especially drugs with a narrow
therapeutic window (Alvarez et al. 2010). Most of the
studies have demonstrated inhibitory effects of flavonoids
on the substrate efflux in cells that either endogenously
expressed these transporters or that were transfected with
them (Morris and Zhang 2006). These ABC-transporter
proteins can affect the oral availability and tissue distri-
bution of the flavonoids also, thereby modifying their
beneficial effects (Brand et al. 2006).
Anti-oxidant properties
In addition to enzymatic oxidation, flavonoid oxidation can
take place via autoxidation (metal-catalyzed oxidation by
dioxygen) and ROS scavenging. The former process can be
related to flavonoid cytotoxicity (ROS production) while
the latter is one of the main anti-oxidant mechanisms. Both
processes may be modulated by flavonoid–protein binding.
Although poorly documented so far, these points could be
important and, for instance, albumin–flavonoid complexes
with an affinity for LDL could act as the true plasma anti-
oxidants participating in the regeneration of a-tocopherol
from the a-tocopheryl radical formed upon scavenging of
LDL-bound lipid peroxyl radicals. In addition, flavonoid–
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protein complexation can be expected to provide protection
to the protein against oxidative degradation.
Since lipid peroxidation is clearly related to the onset of
atherosclerosis and the impairment of membrane functions,
the influence of proteins on the ability of flavonoids to
inhibit lipid peroxidation deserves examination (Peng and
Kuo 2003; Liu et al. 2006; Kumar et al. 2008; Li 2011).
Such investigations have been carried out with BSA and
lecithin liposomes (Heinonen et al. 1998; Sivonova´ et al.
2006). Whereas BSA alone already slows down the for-
mation of lipid hydroperoxides and hexanal, its influence
on the anti-peroxidizing activity of the selected polyphe-
nols is highly dependent on the polyphenolic structure.
Hence, BSA lowers the inhibition of hydroperoxide for-
mation by catechins and caffeic acid, enhances inhibition
by malvidin and rutin, and leaves essentially unchanged
inhibition by quercetin. No clear interpretation based on
polyphenol–BSA binding can be given. One-electron oxi-
dation of protein-bound phenols to form reactive aryloxyl
radicals is a possible pro-oxidant mechanism, since these
radicals can propagate H-atom or electron transfers within
the protein. In addition to phenol–protein covalent cou-
pling, these phenol-mediated oxidative damages to proteins
could be detrimental to their function as enzymes, recep-
tors, and membrane transporters.
Anti-oxidant properties have been reported for isoflav-
ones both in vitro and in vivo (Wei et al. 1995; Wiseman
et al. 1998, 2000; Mitchell et al. 1998). Equol, in model
membrane systems, was a more effective anti-oxidant than
genistein or the parent compound daidzein (Wiseman et al.
1998) and shows structural similarity to the tocopherols.
Daidzein and geinstein showed anti-oxidant action in pri-
mary and cancer lymphocytes (Jurkat cells), both isoflav-
ones increased DNA protection against oxidative damage
and decreased lipid peroxidation (Foti et al. 2005). More-
over, a protective effect was achieved at concentrations
that can be achieved in plasma following soy consumption.
An important aspect of cancer risk is the involvement of
the inflammatory response, which involves the production
of cytokines and proinflammatory oxidants such as the
hypochlorous acid produced by neutrophils and peroxyni-
trite by macrophages, which react with phenolic tyrosine
residues on proteins to form chloro- and nitrotyrosine
(D’Alessandro et al. 2003). It has been reported that neu-
trophil myleloperoxidase chlorinates and nitrates isoflav-
ones and enhances their anti-oxidant properties, thus soy
isoflavones may have potentially protective benefits at sites
of inflammation (D’Alessandro et al. 2003). Anti-oxidant
action could also contribute to anti-cancer ability because
ROS could initiate signal transduction through the mito-
gen-activated protein (MAP) kinases (Wiseman and
Halliwell 1996). There have been a number of reports
relating to the possible anti-oxidant effects of isoflavone
consumption. Soy isoflavone consumption as a soy protein
burger (56 mg isoflavones/day for 17 days) decreased
plasma F2-isoprostane concentrations in healthy young
adults (Wiseman et al. 2000). Consumption of a soy iso-
flavone supplement (50 mg isoflavones, twice a day for
3 weeks) decreased a biomarker of DNA oxidative damage
(white cell 5-hydroxymethyl-20-deoxyuridine concentra-
tions) but did not alter plasma F2-isoprostane concentra-
tions (Djuric et al. 2001). Furthermore, consumption of soy
protein (110 mg isoflavones/day for 4 weeks) decreased
plasma peroxide concentrations and increased total anti-
oxidant status but did not effect a biomarker of oxidative
DNA damage (Bazzoli et al. 2002). It is of considerable
interest that widely differing effects in relation to the
potential benefits to human health are frequently reported
for isoflavones consumed within the food matrix in soy
foods, compared to those consumed in capsule or tablet
form as dietary supplements.
Anti-angiogenesis
Angiogenesis, the formation of new blood vessels, is an
important process which is regulated by endogenous
angiogenic and angiostatic factors. Any alteration in this
tightly regulated process can lead to a persistent and
uncontrolled growth and metastasis of tumors. Flavanoids
have been reported as angiogenesis inhibitors (Tosetti et al.
2002). These inhibitors can cause lack of diffusion of
nutrients and oxygen to rapidly growing cancerous cells due
to anti-angiogenic properties and hence lead to cell death.
Angiogenesis inhibitors can interfere with various steps in
angiogenesis, such as the proliferation and migration of
endothelial cells and lumen formation. A possible mecha-
nism could be inhibition of protein kinases (Oikawa et al.
1992). These enzymes are implicated to play an important
role in signal transduction and are known for their effects on
angiogenesis. Genistein is a potent inhibitor of angiogenesis
in vitro (Fotsis et al. 1993; Kim 2003; Su et al. 2005) and
thus could have therapeutic applications in the treatment of
chronic neovascular diseases including solid tumor growth
(Fotsis et al. 1995) and inhibition of neovascularization of
the eye by genistein has been reported (Kruse et al. 1997;
Joussen et al. 2000; Xu and Yuan 2009). Studies on the
inhibition of cell proliferation and angiogenesis by flavo-
noids in six different cancer cell lines had been reported and
noted that the IC50 of active flavonoids were in the low
micromolar range, physiologically available concentrations
(Fotsis et al. 1997). Isoflavonones (genistein, genistin,
daidzein, and biochanin A) also inhibit growth of murine
and human bladder cancer cell lines by inducing cell cycle
arrest, apoptosis, and angiogenesis (Zhou et al. 1998).
Luteolin has been found to inhibit VEGF-induced angio-
genesis; inhibition of endothelial cell survival and
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proliferation by targeting phosphatidylinositol-3-kinase
action (Bagli et al. 2004). Favot et al. (2003) suggested the
involvement of cyclin-dependent pathway in the inhibitory
effect of delphinidin on angiogenesis. During the last dec-
ade, some more novel molecular targets for the inhibition of
angiogenesis by genistein have been discovered including
tissue factor, endostatin, and angiostatin (Su et al. 2005).
Genistein may enhance the action of transforming
growth factor-b (TGF-b) (Kim et al. 1998; Sathyamoorthy
et al. 2005). This action may be a link between the effects
of genistein in a variety of chronic diseases (Barnes 1998)
including atherosclerosis and hereditary hemorrhagic tel-
angiectasia (the Osler–Weber–Rendu syndrome) in which
defects in TGF-b have been characterized (Johnson et al.
1996). Schindler and Mentlein (2006) determined whether
secondary plant constituents, i.e., flavonoids, tocopherols,
curcumin, and other substances regulate VEGF in human
tumor cells in vitro. It was found that the glycosylated
flavonoids (i.e., naringin, a constituent of citrus fruits, and
rutin, a constituent of cranberries) induced the greatest
response to treatment at the lowest concentration in MDA
human breast cancer cells. Inhibition of VEGF release by
flavonoids, tocopherols, and lovastatin in models of neo-
plastic cells suggests a novel mechanism for mammary
cancer prevention. He et al. (2011) indicate that hispidulin
targets the VEGF receptor 2-mediated PI3K/Akt/mTOR
signaling pathway in endothelial cells, leading to the sup-
pression of pancreatic tumor growth and angiogenesis.
Induce apoptosis and cell cycle arrest
Apoptosis is a programed cell death to eliminate damaged
or unwanted cells. It is regulated by a variety of genes that
can either promote apoptosis or can favor cell survival in
response to internal or external stimuli. Dysregulation of
apoptosis could play a critical role in oncogenesis. Among
these genes, the tumor suppressor p53 plays a pivotal role
in controlling the cell cycle, apoptosis, genomic integrity,
and DNArepair (Bode and Dong 2004) by acting as
transactivator or as transrepressor (Ho et al. 2005). After
activation, p53 can bind to regulatory DNA sequences and
activate the expression of genes involved in cell cycle
inhibition (p21, reprimo, cyclin G1, GADD45), apoptosis
(PERP, NOXA, PUMA, p53AIP1, ASPP1/2, Fas, BAX,
PIDD) and genetic stability (p21, DDB2, MSH2, XPC)
(Carr 2000; Amin et al. 2009). EGCG also activated p53
and BAX in breast carcinoma cells (Roy et al. 2005).
Genistein induced G2/M arrest and apoptosis in human
malignant glioma cell lines by activating p53 and p21
(Schmidt et al. 2008). In addition to p53, mammalian cells
contain two closely related proteins, p63 and p73. EGCG
induces apoptosis by activating p73-dependent expression
of a subset of p53 target genes (Amin et al. 2007).
Nuclear factor-kappa B (NF-rB) family of transcription
factors consists of five members, p50, p52, p65 (Rel A),
c-Rel, and Rel B, which share an N-terminal Rel homology
domain responsible for DNA binding. NF-rB is activated
by free radicals, inflammatory stimuli, cytokines, carcino-
gens, tumor promoters, endotoxins, c-radiation, ultraviolet
(UV) light, and X-rays and induces NF-rB target genes
important for cellular growth and transformation, sup-
pression of apoptosis, invasion, metastasis, chemoresis-
tance, radioresistance, and inflammation. Flavonoids may
block one or more steps in the NF-rB signaling pathway
such as inhibition of the most upstream growth factor
receptors that activate the NF-rB signaling cascade,
translocation of NF-rB to the nucleus, DNA binding of the
dimers, or interactions with the basal transcriptional
machinery (Ju et al. 2007). The NF-rB target genes influ-
enced by the flavonoids include inhibition of Bcl-2 and
Bclx(L), cyclin D1, matrix metalloproteinases (MMP), and
VEGF (Hastak et al. 2003; Li et al. 2006).
Flavonoids have been found to suppress activator pro-
tein-1 (AP-1) activation and modulate AP-1 target genes.
AP-1 is a group of dimeric leucine zipper proteins con-
sisting of Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1,
and Fra-2), Maf (c-Maf, MafB, MafA, MafG/F/K, and Nrl),
and ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) sub-
families (Shaulian and Karin 2002). These proteins form
either homo- or heterodimers and bind either to AP-1 DNA
recognition elements (50-TGAG/CTCA-30) or to cAMP
response elements (50-TGACGTCA-30) and activate their
target genes. Some of the biologic effects of AP-1 are
mediated by gene repression. AP-1-regulated genes include
important modulators of invasion and metastasis, angio-
genesis, proliferation, differentiation, and survival.
Activation of various tyrosine kinases leads to phos-
phorylation, dimerization, and nuclear localization of the
signal transducers and activators of transcription (STAT)
proteins, binding to specific DNA elements and direct
transcription. Constitutive activation of STAT3 and
STAT5 has been implicated in multiple myelomas, lym-
phomas, leukemias, and several solid tumors. Selvendiran
et al. (2006) reported that luteolin inhibited phosphoryla-
tion of STAT3, which targeted it for proteosomal degra-
dation and inhibited the expression of cyclin D1, survivin,
Bcl-x(L), and VEGF.
Luteolin is capable of inducing anti-cancer effects by
inducing cell cycle arrest or apoptosis in oral squamous
cancer cells (Yang et al. 2008), human esophageal, lung,
liver and colon cancer cells (Zhang et al. 2008; Ju et al.
2007). Luteolin inhibited proliferation and induced apop-
tosis of prostate cancer cells in vitro and in xenografts
(Chiu and Lin 2008), with increased efficacy of cisplatin in
gastric cancer cells (Wu et al. 2008). Genistein inhibited P
Ca cell growth in culture by inducing G2/M arrest and
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apoptosis, increased the radiation efficacy against prostate
cancer in cell culture and in vivo models (Lakshman et al.
2008).
Quercetin has been reported to suppress the viability of
HeLa cells in a dose-dependent manner by inducing G2/M
phase cell cycle arrest and mitochondrial apoptosis through
a p53-dependent mechanism (Vidya et al. 2010). Some
characteristic changes in nuclear morphology, phosphati-
dylserine externalization, mitochondrial membrane depo-
larization, modulation of cell-cycle regulatory proteins and
NF-jB family members, upregulation of proapoptotic Bcl-2
family proteins, cytochrome C, Apaf-1 and caspases, and
downregulation of anti-apoptotic Bcl-2 proteins and sur-
viving was reported. Similarly fisetin inhibited the prolif-
eration of bladder cancer cells by inducing apoptosis and
blocking cell-cycle progression in the G0/G1 phase. It
significantly increases the expression of p53 and p21 pro-
teins, and decreases the levels of cyclin D1, cyclin A, CDK4
and CDK2, thereby contributing to cell cycle arrest. In
addition, fisetin increased the expression of Bax and Bak
but decreased the levels of Bcl-2 and Bcl-xL and subse-
quently triggered mitochondrial apoptotic pathway (Li et al.
2011a, b). Pretreatment with chrysin could increase TRAIL-
induced degradation of caspase 3, caspase 8, PARP protein.
Z-VAD- fmk, which is a pan-cascade inhibitor, could
inhibit the apoptosis enhanced by combination of chrysin
and TRAIL (Li et al. 2011a, b). 2,2 dihydroxychalcone
(DHC) and fisetin, induced S and G2 phase cell-cycle arrest
in LNCaP and PC3 prostate cancer cells by downregulation
in gene expression of 75 key cell cycle (G2 and M phases)
and enhanced expression of 50 stress response gene.
Thereby, DHC and fisetin induced apoptosis, but not
accelerated senescence in prostate cells (Haddad 2008). The
study on diethyl 5,7,40-trihydroxy flavanone N-phenyl
hydrazone (N101-2), a synthesized naringenin derivative
exhibited cervical cancer cell growth inhibition by arresting
the cell cycle at sub-G1 phase, activating mitochondria-
emanated intrinsic and Fas-mediated extrinsic signaling
pathways, and inhibiting the PI3K/AKT pathway in CaSki
and SiHa human cervical cancer cells (Kim et al. 2012).
Summary and conclusions
Flavonoids greatly influence the cascade of immunological
events associated with the development and progression of
cancer. One has to understand the mechanism how these
flavonoids get accumulated in cellular organelles and tis-
sues once they enter inside. Flavonoids have the potential
of modulatng many biological events in cancer such as
apoptosis, vascularization, cell differentiation, cell prolif-
eration, etc. A strong correlation persists between flavo-
noid-induced modulation of kinases with apoptosis, cell
proliferation and tumor cell invasive behavior in vitro.
Also, some of the dietary flavonoids have been known to
display in vivo anti-tumor activity and repress in vivo
angiogenesis. The cross talk between flavonoids and the
key enzymes related to neoplastic cells and metastasis has
to be understood in vitro and in vivo as well, providing new
insights for fighting against cancer.
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